Novo Nordisk, European markets

Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said
European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recovery
European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 was up by around 0.3% during morning deals, with all sectors in positive territory.
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowes
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
European markets set to rise in shortened session ahead of Christmas
European markets are set to open higher on Tuesday, in a shortened trading session for Christmas Eve. London's FTSE 100 is slated to gain 56 points to open at 8,140, according to data from IG, while France's CAC 40 index is expected to start the session 46 points higher at 7,
European markets turn green ahead of Christmas break
London (UKX) +0.33% will close early for Christmas. Germany (DAX:IND) closed for Chritsmas France (CAC:IND) +0.38% set to close early. Prime Minister François Bayrou pledged to cut the country's budget deficit to near 5%.
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...